✦ LIBER ✦

Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy

✍ Scribed by Pirus Ghadjar; Tamara Keller; Cyrill A. Rentsch; Bernhard Isaak; Frank Behrensmeier; Andrea Stroux; George N. Thalmann; Daniel M. Aebersold

Book ID: 108074931
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 223 KB
Volume: 8
Category: Article
ISSN: 1538-4721
DOI: 10.1016/j.brachy.2008.09.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Five-year biochemical and clinical outco

Five-year biochemical and clinical outcomes for high-dose-rate and low-dose-rate brachytherapy in the setting of favorable risk prostate cancer

✍ Samuel McGrath; Alvaro A. Martinez; D. Jeffrey Demanes; Michel Ghilezan; Lionel 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 46 KB

High-dose-rate brachytherapy as monother

High-dose-rate brachytherapy as monotherapy for favorable-risk prostate cancer. Improved toxicity profile with real-time transrectal ultrasound 3D vs 2D treatment planning and dosimetry

✍ Michel Ghilezan; Gary S. Gustafson; Peter Chen Dan Krauss; Evelyn Sebastian; Leo 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Correlation Between Dosimetric Parameter

Correlation Between Dosimetric Parameters and Late Rectal and Urinary Toxicities in Patients Treated With High-Dose-Rate Brachytherapy Used as Monotherapy for Prostate Cancer

✍ Koji Konishi; Yasuo Yoshioka; Fumiaki Isohashi; Iori Sumida; Yoshifumi Kawaguchi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Urethral toxicity vs. cancer control—Les

Urethral toxicity vs. cancer control—Lessons to be learned from high–dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer

✍ Pirus Ghadjar; Cyrill A. Rentsch; Bernhard Isaak; Frank Behrensmeier; George N. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 360 KB

Impact of age on biochemical control in

Impact of age on biochemical control in a cohort of intermediate- and high-risk prostate cancer patients treated with high-dose-rate brachytherapy boost combined with pelvic external beam radiation therapy

✍ Amy L. Limbacher; Michel Ghilezan; Gary Gustafson; Peter Y. Chen; Christine Mitc 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 80 KB